Sage Therapeutics, Inc. (11)

Browse by Contract Category

Contracts

2014 Employee Stock Purchase Plan, as amended (Filed With SEC on August 2, 2022)
Amended and Restated Non-Employee Director Compensation Policy, dated April 8, 2022 (Filed With SEC on August 2, 2022)
Offer Letter by and between the Registrant and Christopher Benecchi, dated September 13, 2021 (Filed With SEC on November 2, 2021)
Amendment No. 1 to Exclusive License Agreement, by and between the Registrant and Washington University, dated as of July 13, 2021 (Filed With SEC on November 2, 2021)
Side Letter to Biogen Collaboration and License Agreement, by and among the Registrant, Biogen MA Inc. and Biogen International GmbH, dated October 21, 2021 (Filed With SEC on November 2, 2021)
Eighth Amendment to Lease by and between ARE-MA Region No. 38, LLC and the Registrant, dated March 29, 2019 (Filed With SEC on August 6, 2019)
Severance and Change in Control Agreement between the Registrant and Christopher Benecchi, dated September 13, 2021 (Filed With SEC on November 2, 2021)
Separation Agreement, by and between the Registrant and Michael Cloonan, dated March 12, 2021 (Filed With SEC on May 4, 2021)
Form of Performance-Based Restricted Stock Unit Award Agreement Under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan (Filed With SEC on August 10, 2020)
Description of Securities (Filed With SEC on February 27, 2020)
Underwriting Agreement, dated as of February 25, 2019, by and among Sage Therapeutics, Inc. and Goldman Sachs & Co. LLC. and J.P. Morgan Securities LLC (Filed With SEC on February 27, 2019)